International Doctors Visit Smartee HQ and Share Insights on Next-Generation Orthodontics
SHANGHAI, Sept. 19, 2025 /PRNewswire/ -- Smartee Denti-Technology hosted a delegation of orthodontic specialists from Europe and Asia at its Shanghai headquarters and digital production facilities. The visit combined advanced mandibular repositioning lectures, clinical visits, and cultural exchange, highlighting how Smartee's innovations — from mandibular repositioning solutions to pediatric orthodontic systems — are shaping next-generation orthodontic care. International...
SingHealth’s Healthier EAST @ SG joins WHO’s Global Network of Age-Friendly Cities
Healthier EAST @ SG, a comprehensive, multi-agency initiative led by SingHealth, has been inducted into the World Health Organization (WHO)'s Global Network for Age-Friendly Cities and Communities (GNAFCC). The landmark initiative impacts over 610,000 residents in the east of Singapore through innovative health and social programmes. The recognition places Eastern...
2025 IMS | IASO Bio Highlights Three-Year Follow-Up Data of CAR-T Cell Therapy Fucaso for Multiple Myeloma Treatment
SHANGHAI, NANJING, China and PLEASANTON, Calif., Sept. 19, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies, today announced that the 36-month long-term follow-up data from the FUMANBA-1 study of its independently developed fully human anti-BCMA CAR-T cell therapy Fucaso (Equecabtagene Autoleucel, Eque-cel), for the treatment of...
LabConnect Appoints Bill Finger as Senior Vice President, Global Strategic Services
JOHNSON CITY, Tenn., Sept. 19, 2025 /PRNewswire/ -- LabConnect is pleased to announce the appointment of Bill Finger as Senior Vice President, Global Strategic Services, effective Wednesday, September 10, 2025. Bill brings more than 25 years of diagnostics and clinical research experience, with deep expertise in the global lab and pharmacy industry. As a senior executive, he...
QL Biopharm reports Phase 2 results of a monthly dose study evaluating zovaglutide, a novel, extended half-life GLP-1 receptor agonist at EASD 2025
Patients who received zovaglutide at a once-monthly dose of 160 mg experienced a 13.8% reduction in body weight at 24 weeks, highly comparable to reductions observed in patients who received 80 mg every other week (12.5%) The overall safety and tolerability of zovaglutide were consistent and comparable with the GLP-1 receptor agonist class of obesity management drugs...
NYSE Content Advisory: Pre-Market Update + Fed cuts interest rates by 0.25%
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-Market Update + Fed cuts interest rates by 0.25%...
Grace Lu rejoining Russell Reynolds Associates Singapore as Managing Director for Healthcare Practice
SINGAPORE, Sept. 18, 2025 /PRNewswire/ -- Russell Reynolds Associates (RRA), the leading global leadership advisory firm, is pleased to announce that Grace Lu is rejoining the Singapore office as a senior member of the Healthcare Practice. Previously based in Beijing, Grace returns to Singapore to lead the firm's Healthcare Practice across Asia Pacific,...
Innovent’s Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
SAN FRANCISCO and SUZHOU, China, Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported a clinical update on IBI324 (Ollin R&D code: OLN324). IBI324 (OLN324)...
Investing in Futures: Education Cannot Wait Reaches 14 Million Children in Crises Worldwide
New ECW Results Report highlights transformative education outcomes for children and adolescents in emergencies and protracted crises and calls for urgent funding to sustain progress. NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Education Cannot Wait (ECW), the global fund for education in emergencies and protracted crises in the United Nations, today launched its Investing in Futures: 2024 Annual Results Report...
Neuronata-R® Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway
Meaningful improvements confirmed in slow-progressor subgroup; biomarker reductions support precision-medicine approach and potential FDA accelerated pathway SEOUL, South Korea, Sept. 18, 2025 /PRNewswire/ -- CorestemChemon Inc. (KOSDAQ: 166480) announced today that it has presented key findings from the Phase 3 ALSummit trial of Neuronata-R® (lenzumestrocel), an autologous bone marrow-derived mesenchymal stem cell (MSC) therapy for amyotrophic lateral sclerosis...
